Press releases

Company believes the finding of patent infringement is in error and will request the judge to overturn it

Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company

Studies evaluated the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease

TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent

TAXUS ATLAS studies also reinforce deliverability of TAXUS® Liberte® drug-eluting stent in long lesions and small vessels

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease

Data showed continued low incidences of adverse events and repeat revascularization through two years in complex patients

"The quarter represented a turn for us, with a number of positive developments," said Jim Tobin, President and Chief Executive Officer

Approximately 2,300 positions to be eliminated worldwide

Schedule of Company events for the Cardiovascular Research Foundation's (CRF) 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium